Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HENRY SCHEIN INCHSIC · Entity 3536 | Director | March 06, 2026 | March 09, 2026 |
| HarborOne Bancorp, Inc.HONE · Entity 73670 | EVP, Chief Banking Officer | November 01, 2025 | November 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HENRY SCHEIN INC
Report date March 06, 2026 · Filed March 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 23,153 |
Reported balance
After 2026-03-06 transaction · row 1
1 source rowRow 1 · 2026-03-06 · Grant · Acquired 2,577 · Balance 23,153 F1: Acquired pursuant to the Issuer's 2023 Non-Employee Director Stock Incentive Plan. Subject to certain exceptions, such restricted stock units will vest subject to (i) the passage of a specified period of time (12-months cliff vesting) and (ii) the reporting person's continued performance of services for the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquired pursuant to the Issuer's 2023 Non-Employee Director Stock Incentive Plan. Subject to certain exceptions, such restricted stock units will vest subject to (i) the passage of a specified period of time (12-months cliff vesting) and (ii) the reporting person's continued performance of services for the Issuer.
HarborOne Bancorp, Inc.
Report date November 01, 2025 · Filed November 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-11-01 transaction · row 1
1 source rowRow 1 · 2025-11-01 · Disposition to issuer · Disposed 11,972 · Balance 0 F1: Pursuant to the merger agreement, dated as of April 24, 2025, by and among Eastern Bankshares, Inc. ("Eastern"), Eastern Bank, HarborOne Bancorp, Inc. ("HarborOne"), and HarborOne Bank (the "Merger Agreement"), ent, each share of HarborOne common stock was converted into the right to receive, at the election of the holder, either (i) $12.00 in cash or (ii) 0.765 shares of Eastern common stock (the "Exchange Ratio"), subject to certain proration provisions contained in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the merger agreement, dated as of April 24, 2025, by and among Eastern Bankshares, Inc. ("Eastern"), Eastern Bank, HarborOne Bancorp, Inc. ("HarborOne"), and HarborOne Bank (the "Merger Agreement"), ent, each share of HarborOne common stock was converted into the right to receive, at the election of the holder, either (i) $12.00 in cash or (ii) 0.765 shares of Eastern common stock (the "Exchange Ratio"), subject to certain proration provisions contained in the Merger Agreement.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SomaLogic, Inc.
Report date January 05, 2024 · Filed January 09, 2024
Section 16 reporting ended · disclosed 2024-01-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 1
1 source rowRow 1 · 2024-01-05 · Disposition to issuer · Disposed 23,430 · Balance 0 F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.77 · Expires 2030-05-11 | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-05 · Disposition to issuer · Disposed 16,762 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F3: The option is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.77 · Expires 2030-05-11 | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-05 · Disposition to issuer · Disposed 33,524 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F5: The option vested as to 1/4th of the total grant on May 12, 2021, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.77 · Expires 2031-02-18 | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-05 · Disposition to issuer · Disposed 20,952 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F3: The option is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2031-10-27 | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-01-05 · Disposition to issuer · Disposed 46,705 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F6: The option vested as to 1/4th of the total grant on October 27, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08 · Expires 2023-03-01 | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-01-05 · Disposition to issuer · Disposed 20,600 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F3: The option is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2033-03-16 | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-01-05 · Disposition to issuer · Disposed 20,600 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F7: The option shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-01-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-01-05 · Disposition to issuer · Disposed 3,430 · Balance 0 F8: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F10: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F9: The RSUs shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger").
F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock.
F3: The option is fully vested and exercisable.
F4: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions.
F5: The option vested as to 1/4th of the total grant on May 12, 2021, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
F6: The option vested as to 1/4th of the total grant on October 27, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
F7: The option shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date.
F8: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration.
F9: The RSUs shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date.
F10: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2026 Filed Mar 9, 2026 20:33 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantCommon Stock, par value $0.01 per share | 2,577 | $0.00 | $0.00 |
DisclosureSEC source: 0001743156-26-000002 · ownership.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,153 F1 · shares: Acquired pursuant to the Issuer's 2023 Non-Employee Director Stock Incentive Plan. Subject to certain exceptions, such restricted stock units will vest subject to (i) the passage of a specified period of time (12-months cliff vesting) and (ii) the reporting person's continued performance of services for the Issuer. Read SEC document |
| November 01, 2025 Filed Nov 3, 2025 16:49 UTC | HarborOne Bancorp, Inc. HONE · Entity 73670 | Disposition to issuerCommon Stock | 11,972 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-105605 · tm2529949-8_4seq1.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · EVP, Chief Banking Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the merger agreement, dated as of April 24, 2025, by and among Eastern Bankshares, Inc. ("Eastern"), Eastern Bank, HarborOne Bancorp, Inc. ("HarborOne"), and HarborOne Bank (the "Merger Agreement"), ent, each share of HarborOne common stock was converted into the right to receive, at the election of the holder, either (i) $12.00 in cash or (ii) 0.765 shares of Eastern common stock (the "Exchange Ratio"), subject to certain proration provisions contained in the Merger Agreement. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 21:37 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | Tax withholdingCommon Stock, par value $0.01 per share | 653 | $71.46 | $46,663.38 |
DisclosureSEC source: 0000950170-25-034780 · ownership.xml · nonDerivative · entry 3 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,576 F3 · shares: Represents the surrender of shares to the Issuer to satisfy the reporting person's tax withholding obligation upon the vesting of the reporting person's 2019 grant of time-based restricted stock units, which vested on March 5, 2020 but per the reporting person's election the payment date was deferred until March 5, 2025. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:37 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantCommon Stock, par value $0.01 per share | 2,844 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-034780 · ownership.xml · nonDerivative · entry 2 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,229 F2 · shares: Acquired pursuant to the Issuer's 2023 Non-Employee Director Stock Incentive Plan. Subject to certain exceptions, such restricted stock/units will vest subject to (i) the passage of a specified period of time and (i) the reporting person's continued performance of services for the Issuer. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:37 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | Tax withholdingCommon Stock, par value $0.01 per share | 572 | $70.31 | $40,217.32 |
DisclosureSEC source: 0000950170-25-034780 · ownership.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,385 F1 · shares: Represents the surrender of shares to the Issuer to satisfy the reporting person's tax withholding obligation upon the vesting of the reporting person's 2024 grant of time-based restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:43 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | Tax withholdingCommon Stock, par value $0.01 per share | 613 | $70.81 | $43,406.53 |
DisclosureSEC source: 0000950170-25-032266 · ownership.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,957 F1 · shares: Represents the surrender of shares to the Issuer to satisfy the reporting person's tax withholding obligation upon the distribution of the reporting person's March 3, 2021 grant of time-based restricted stock/units which vested on March 3, 2022 but per the reporting person's election the payment date was deferred until March 3, 2025. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 10:50 UTC | HarborOne Bancorp, Inc. HONE · Entity 73670 | GrantCommon Stock | 3,451 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-007644 · form4.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,972 F1 · shares: Acquisition represents award of restricted stock for no consideration. The restricted stock award vests in full on March 3, 2026. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:14 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | Tax withholdingCommon Stock, par value $0.01 per share | 714 | $68.51 | $48,916.14 |
DisclosureSEC source: 0000950170-24-071904 · ownership.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,570 F1 · shares: Represents the surrender of shares to the Issuer to satisfy the reporting person's tax withholding obligation upon the distribution of the reporting person's June 8, 2018 grant of time-based restricted stock/units which vested on June 8, 2019 but per the reporting person's election the payment date was deferred until June 8, 2024. (Actual payment date of June 8, 2024 was a non-business day so distribution occurred on the preceding business day.) Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:59 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantCommon Stock, par value $0.01 per share | 2,604 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026203 · ownership.xml · nonDerivative · entry 2 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,284 F2 · shares: Acquired pursuant to the Issuer's 2023 Non-Employee Director Stock Incentive Plan. Subject to certain exceptions, such restricted stock/units will vest subject to (i) the passage of a specified period of time and (i) the reporting person's continued performance of services for the Issuer. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 15:32 UTC | HarborOne Bancorp, Inc. HONE · Entity 73670 | GrantCommon Stock | 3,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-008081 · form4.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,521 F1 · shares: Acquisition represents award of restricted stock for no consideration. This restricted stock award vests in full on March 1, 2025. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:59 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | Tax withholdingCommon Stock, par value $0.01 per share | 495 | $76.88 | $38,055.60 |
DisclosureSEC source: 0000950170-24-026203 · ownership.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,680 F1 · shares: Represents the surrender of shares to the Issuer to satisfy the reporting person's tax withholding obligation upon the vesting of the reporting person's March 1, 2023 grant of time-based restricted stock/units. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:40 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerRestricted Stock Unit · Derivative | 3,430 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001322 · doc4.xml · derivative · entry 8 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,430 shares Expires not disclosed F8 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F10 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F9 · derivative.exercise_date: The RSUs shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date. F9 · derivative.expiration_date: The RSUs shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:40 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerStock Option (Right to buy) · Derivative | 20,600 | Not disclosed Strike: $2.30 | Not disclosed |
DisclosureSEC source: 0001209191-24-001322 · doc4.xml · derivative · entry 7 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,600 shares Expires 2033-03-16 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F7 · derivative.exercise_date: The option shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:40 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerStock Option (Right to buy) · Derivative | 20,600 | Not disclosed Strike: $9.08 | Not disclosed |
DisclosureSEC source: 0001209191-24-001322 · doc4.xml · derivative · entry 6 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,600 shares Expires 2023-03-01 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:40 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerStock Option (Right to buy) · Derivative | 46,705 | Not disclosed Strike: $11.85 | Not disclosed |
DisclosureSEC source: 0001209191-24-001322 · doc4.xml · derivative · entry 5 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,705 shares Expires 2031-10-27 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F6 · derivative.exercise_date: The option vested as to 1/4th of the total grant on October 27, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:40 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerStock Option (Right to buy) · Derivative | 20,952 | Not disclosed Strike: $4.77 | Not disclosed |
DisclosureSEC source: 0001209191-24-001322 · doc4.xml · derivative · entry 4 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,952 shares Expires 2031-02-18 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:40 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerStock Option (Right to buy) · Derivative | 33,524 | Not disclosed Strike: $4.77 | Not disclosed |
DisclosureSEC source: 0001209191-24-001322 · doc4.xml · derivative · entry 3 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,524 shares Expires 2030-05-11 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F5 · derivative.exercise_date: The option vested as to 1/4th of the total grant on May 12, 2021, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:40 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerStock Option (Right to buy) · Derivative | 16,762 | Not disclosed Strike: $4.77 | Not disclosed |
DisclosureSEC source: 0001209191-24-001322 · doc4.xml · derivative · entry 2 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,762 shares Expires 2030-05-11 F4 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:40 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerCommon Stock | 23,430 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001322 · doc4.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:22 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerWarrant to purchase common stock (Right to buy) · Derivative | 4,346,669 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001209191-24-001314 · doc4.xml · derivative · entry 10 Margulies Anne H. · CIK 0001743156 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By CMLS Holdings II LLC Disclosed balance after: 0 Underlying: Common Stock · 4,346,669 shares Expires 2026-09-01 F15 · price: Pursuant to the Merger Agreement, each warrant to purchase Company Common Stock was treated in accordance with its terms on and after the Effective Time and each warrant will convert into the right to receive, upon exercise of such warrant, the number of shares of Parent Common Stock equal to multiplying the number of shares of Company Common Stock subject to such warrant by the Exchange Ratio. F14 · derivative.exercise_date: Each warrant is exercisable to purchase one share of Company Common Stock at a price of $11.50 per share, subject to adjustment, as described in the Issuer's Annual Report on Form 10-K, for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on March 28, 2023. F3 · ownership.nature: The shares are held of record by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Mr. Casdin, who, as a member of the Board of Managers of CMLS Holdings II, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II. Mr. Casdin may be deemed to have or share beneficial ownership of the securities held by CMLS Holdings II, which include such shares and the warrants referenced in Table II. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:22 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerRestricted Stock Unit · Derivative | 3,430 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001314 · doc4.xml · derivative · entry 9 Margulies Anne H. · CIK 0001743156 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,430 shares Expires not disclosed F11 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F13 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F12 · derivative.exercise_date: The RSUs shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date. F12 · derivative.expiration_date: The RSUs shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:22 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerStock Option (Right to buy) · Derivative | 20,600 | Not disclosed Strike: $2.30 | Not disclosed |
DisclosureSEC source: 0001209191-24-001314 · doc4.xml · derivative · entry 8 Margulies Anne H. · CIK 0001743156 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,600 shares Expires 2033-03-16 F7 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F10 · derivative.exercise_date: The option shall be 100% vested on March 17, 2024, subject to the continued service of the Reporting Person on such vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:22 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerStock Option (Right to buy) · Derivative | 20,600 | Not disclosed Strike: $9.08 | Not disclosed |
DisclosureSEC source: 0001209191-24-001314 · doc4.xml · derivative · entry 7 Margulies Anne H. · CIK 0001743156 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,600 shares Expires 2032-02-29 F7 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F9 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:22 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerStock Option (Right to buy) · Derivative | 46,705 | Not disclosed Strike: $11.85 | Not disclosed |
DisclosureSEC source: 0001209191-24-001314 · doc4.xml · derivative · entry 6 Margulies Anne H. · CIK 0001743156 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,705 shares Expires 2031-10-26 F7 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F8 · derivative.exercise_date: The option vested as to 1/4th of the total grant on October 27, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:22 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerStock Option (Right to buy) · Derivative | 41,905 | Not disclosed Strike: $4.77 | Not disclosed |
DisclosureSEC source: 0001209191-24-001314 · doc4.xml · derivative · entry 5 Margulies Anne H. · CIK 0001743156 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,905 shares Expires 2031-02-18 F7 · price: Pursuant to the Merger Agreement, each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F6 · derivative.exercise_date: The option vested as to 1/4th of the total grant on February 19, 2022, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:22 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerCommon Stock | 2,472,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001314 · doc4.xml · nonDerivative · entry 4 Margulies Anne H. · CIK 0001743156 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Casdin Private Growth Equity Fund, L.P. Disclosed balance after: 0 F1 · price: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. F5 · ownership.nature: The shares held by Casdin Private Growth Equity Fund, L.P. may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Private Growth Equity GP, LLC, the general partner of Casdin Private Growth Equity Fund, L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Private Growth Equity GP, LLC. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:22 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerCommon Stock | 10,132,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001314 · doc4.xml · nonDerivative · entry 3 Margulies Anne H. · CIK 0001743156 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Casdin Master Fund, L.P. Disclosed balance after: 0 F1 · price: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, LP (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:22 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerCommon Stock | 6,800,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001314 · doc4.xml · nonDerivative · entry 2 Margulies Anne H. · CIK 0001743156 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By CMLS Holdings II LLC Disclosed balance after: 0 F1 · price: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. F3 · ownership.nature: The shares are held of record by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Mr. Casdin, who, as a member of the Board of Managers of CMLS Holdings II, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II. Mr. Casdin may be deemed to have or share beneficial ownership of the securities held by CMLS Holdings II, which include such shares and the warrants referenced in Table II. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:22 UTC | SomaLogic, Inc. SLGC · Entity 95310 | Disposition to issuerCommon Stock | 3,430 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001314 · doc4.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.0001 per share (the "Company Common Stock"), was converted into the right to receive 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001(the "Parent Common Stock") and cash in lieu of fractional shares of the Parent Common Stock. Read SEC document |
| March 17, 2023 Filed Mar 22, 2023 06:03 UTC | SomaLogic, Inc. SLGC · Entity 95310 | GrantEmployee Stock Option (right to buy) · Derivative | 20,600 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001213900-23-021846 · ownership.xml · derivative · entry 2 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,600 Underlying: Common Stock, par value $0.0001 · 20,600 shares Expires 2033-03-16 F1 · derivative.exercise_date: 100% of the shares underlying the option vest one year after the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| March 17, 2023 Filed Mar 22, 2023 06:03 UTC | SomaLogic, Inc. SLGC · Entity 95310 | GrantCommon Stock | 3,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-021846 · ownership.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,860 Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 15:18 UTC | HarborOne Bancorp, Inc. HONE · Entity 73670 | GrantCommon Stock | 2,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-008274 · form4.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,177 F1 · shares: Acquisition represents award of restricted stock for no consideration. This restricted stock award vests in full on March 1, 2024. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:49 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantCommon Stock, par value $0.01 per share | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015625 · doc4.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,175 F1 · shares: Acquired pursuant to the Issuer's 2015 Non-Employee Director Stock Incentive Plan. Subject to certain exceptions, such restricted stock/units will vest subject to (i) the passage of a specified period of time and (ii) the reporting person's continued performance of services for the Issuer. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 21:21 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantDeferred Compensation Plan Phantom Stock · Derivative | 336 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-000198 · doc4.xml · derivative · entry 2 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,190 Underlying: Common Stock, par value $0.01 per share · 336 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of the Issuer's common stock. F2 · shares: Represents the number of shares of phantom stock credited to the reporting person's phantom stock account pursuant to the Issuer's Non-Employee Director Deferred Compensation Plan (the "Plan"), representing an exempt transaction under the Plan. The number of shares of phantom stock credited to the reporting person's phantom stock account is determined by dividing the amount of deferred eligible director fees by the closing price of a share of Issuer common stock on the award date. F3 · derivative.exercise_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F3 · derivative.expiration_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F4 · balance_after: Represents the aggregate number of shares of phantom stock allocated to the reporting person under the Plan as of the award date based on the closing price of a share of the Issuer's common stock on the award date. Read SEC document |
| September 23, 2022 Filed Sep 26, 2022 20:56 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantDeferred Compensation Plan Phantom Stock · Derivative | 399 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-051256 · doc4.xml · derivative · entry 2 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,854 Underlying: Common Stock, par value $0.01 per share · 399 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of the Issuer's common stock. F2 · shares: Represents the number of shares of phantom stock credited to the reporting person's phantom stock account pursuant to the Issuer's Non-Employee Director Deferred Compensation Plan (the "Plan"), representing an exempt transaction under the Plan. The number of shares of phantom stock credited to the reporting person's phantom stock account is determined by dividing the amount of deferred eligible director fees by the closing price of a share of Issuer common stock on the award date. F3 · derivative.exercise_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F3 · derivative.expiration_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F4 · balance_after: Represents the aggregate number of shares of phantom stock allocated to the reporting person under the Plan as of the award date based on the closing price of a share of the Issuer's common stock on the award date. Read SEC document |
| August 01, 2022 Filed Jan 23, 2023 15:18 UTC | HarborOne Bancorp, Inc. HONE · Entity 73670 | GrantCommon Stock | 1,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002026 · form4.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,320 F1 · shares: Acquisition represents award of restricted stock for no consideration. This restricted stock vests in full on August 1, 2023. Read SEC document |
| June 24, 2022 Filed Jun 27, 2022 21:34 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantDeferred Compensation Plan Phantom Stock · Derivative | 348 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039509 · doc4.xml · derivative · entry 2 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,456 Underlying: Common Stock, par value $0.01 per share · 348 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of the Issuer's common stock. F2 · shares: Represents the number of shares of phantom stock credited to the reporting person's phantom stock account pursuant to the Issuer's Non-Employee Director Deferred Compensation Plan (the "Plan"), representing an exempt transaction under the Plan. The number of shares of phantom stock credited to the reporting person's phantom stock account is determined by dividing the amount of deferred eligible director fees by the closing price of a share of Issuer common stock on the award date. F3 · derivative.exercise_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F3 · derivative.expiration_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F4 · balance_after: Represents the aggregate number of shares of phantom stock allocated to the reporting person under the Plan as of the award date based on the closing price of a share of the Issuer's common stock on the award date. Read SEC document |
| March 25, 2022 Filed Mar 28, 2022 20:12 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantDeferred Compensation Plan Phantom Stock · Derivative | 306 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021308 · doc4.xml · derivative · entry 2 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,106 Underlying: Common Stock, par value $0.01 per share · 306 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of the Issuer's common stock. F2 · shares: Represents the number of shares of phantom stock credited to the reporting person's phantom stock account pursuant to the Issuer's Non-Employee Director Deferred Compensation Plan (the "Plan"), representing an exempt transaction under the Plan. The number of shares of phantom stock credited to the reporting person's phantom stock account is determined by dividing the amount of deferred eligible director fees by the closing price of a share of Issuer common stock on the award date. F3 · derivative.exercise_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F3 · derivative.expiration_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F4 · balance_after: Represents the aggregate number of shares of phantom stock allocated to the reporting person under the Plan as of the award date based on the closing price of a share of the Issuer's common stock on the award date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 23:50 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantCommon Stock, par value $0.01 per share | 2,028 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-020138 · doc4.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,925 F1 · shares: Acquired pursuant to the Issuer's 2015 Non-Employee Director Stock Incentive Plan. Subject to certain exceptions, such restricted stock/units will vest subject to (i) the passage of a specified period of time and (ii) the reporting person's continued performance of services for the Issuer. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 19:12 UTC | SomaLogic, Inc. SLGC · Entity 95310 | GrantEmployee Stock Option (right to buy) · Derivative | 20,600 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001743156-22-000001 · primary_doc.xml · derivative · entry 2 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,600 Underlying: Common Stock, par value $0.0001 · 20,600 shares Expires 2032-02-29 F1 · derivative.exercise_date: 100% of the shares underlying the option vest one year after the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 19:12 UTC | SomaLogic, Inc. SLGC · Entity 95310 | GrantCommon Stock | 3,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001743156-22-000001 · primary_doc.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,430 Read SEC document |
| December 23, 2021 Filed Dec 27, 2021 21:12 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantDeferred Compensation Plan Phantom Stock · Derivative | 359 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-071244 · doc4.xml · derivative · entry 2 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,801 Underlying: Common Stock, par value $0.01 per share · 359 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of the Issuer's common stock. F2 · shares: Represents the number of shares of phantom stock credited to the reporting person's phantom stock account pursuant to the Issuer's Non-Employee Director Deferred Compensation Plan (the "Plan"), representing an exempt transaction under the Plan. The number of shares of phantom stock credited to the reporting person's phantom stock account is determined by dividing the amount of deferred eligible director fees by the closing price of a share of Issuer common stock on the award date. F3 · derivative.exercise_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F3 · derivative.expiration_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F4 · balance_after: Represents the aggregate number of shares of phantom stock allocated to the reporting person under the Plan as of the award date based on the closing price of a share of the Issuer's common stock on the award date. Read SEC document |
| October 27, 2021 Filed Dec 13, 2021 17:16 UTC | SomaLogic, Inc. SLGC · Entity 95310 | GrantEmployee Stock Option (right to buy) · Derivative | 46,705 | $0.00 Strike: $11.85 | $0.00 |
DisclosureSEC source: 0001062993-21-012793 · form4.xml · derivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,705 Underlying: Common Stock, par value $0.0001 · 46,705 shares Expires 2031-10-26 F1 · derivative.exercise_date: 25% of the shares underlying the option vest one year after the grant date, then the remaining shares vest in equal monthly installments thereafter starting on the 1st of following full month until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| September 24, 2021 Filed Sep 27, 2021 20:23 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantDeferred Compensation Plan Phantom Stock · Derivative | 344 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057781 · doc4.xml · derivative · entry 2 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,440 Underlying: Common Stock, par value $0.01 per share · 344 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of the Issuer's common stock. F2 · shares: Represents the number of shares of phantom stock credited to the reporting person's phantom stock account pursuant to the Issuer's Non-Employee Director Deferred Compensation Plan (the "Plan"), representing an exempt transaction under the Plan. The number of shares of phantom stock credited to the reporting person's phantom stock account is determined by dividing the amount of deferred eligible director fees by the closing price of a share of Issuer common stock on the award date. F3 · derivative.exercise_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F3 · derivative.expiration_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F4 · balance_after: Represents the aggregate number of shares of phantom stock allocated to the reporting person under the Plan as of the award date based on the closing price of a share of the Issuer's common stock on the award date. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 16:05 UTC | SomaLogic, Inc. SLGC · Entity 95310 | PurchaseCommon Stock, par value $0.0001 | 20,000 | $11.46 | $229,200.00 |
DisclosureSEC source: 0001213900-21-048394 · ownership.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.18 to $11.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 20:30 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantDeferred Compensation Plan Phantom Stock · Derivative | 358 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043659 · doc4.xml · derivative · entry 2 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,096 Underlying: Common Stock, par value $0.01 per share · 358 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of the Issuer's common stock. F2 · shares: Represents the number of shares of phantom stock credited to the reporting person's phantom stock account pursuant to the Issuer's Non-Employee Director Deferred Compensation Plan (the "Plan"), representing an exempt transaction under the Plan. The number of shares of phantom stock credited to the reporting person's phantom stock account is determined by dividing the amount of deferred eligible director fees by the closing price of a share of Issuer common stock on the award date. F3 · derivative.exercise_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F3 · derivative.expiration_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F4 · balance_after: Represents the aggregate number of shares of phantom stock allocated to the reporting person under the Plan as of the award date based on the closing price of a share of the Issuer's common stock on the award date. Read SEC document |
| March 26, 2021 Filed Mar 29, 2021 20:42 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantDeferred Compensation Plan Phantom Stock · Derivative | 428 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023454 · doc4.xml · derivative · entry 2 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,739 Underlying: Common Stock, par value $0.01 per share · 428 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of the Issuer's common stock. F2 · shares: Represents the number of shares of phantom stock credited to the reporting person's phantom stock account pursuant to the Issuer's Non-Employee Director Deferred Compensation Plan (the "Plan"), representing an exempt transaction under the Plan. The number of shares of phantom stock credited to the reporting person's phantom stock account is determined by dividing the amount of deferred eligible director fees by the closing price of a share of Issuer common stock on the award date. F3 · derivative.exercise_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F3 · derivative.expiration_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F4 · balance_after: Represents the aggregate number of shares of phantom stock allocated to the reporting person under the Plan as of the award date based on the closing price of a share of the Issuer's common stock on the award date. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 21:50 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantCommon Stock, par value $0.01 per share | 2,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018266 · doc4.xml · nonDerivative · entry 1 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,897 F1 · shares: Acquired pursuant to the Issuer's 2015 Non-Employee Director Stock Incentive Plan. Subject to certain exceptions, such restricted stock/units will vest subject to (i) the passage of a specified period of time and (ii) the reporting person's continued performance of services for the Issuer. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 21:11 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantDeferred Compensation Plan Phantom Stock · Derivative | 442 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065166 · doc4.xml · derivative · entry 2 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,311 Underlying: Common Stock, par value $0.01 per share · 442 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of the Issuer's common stock. F2 · shares: Represents the number of shares of phantom stock credited to the reporting person's phantom stock account pursuant to the Issuer's Non-Employee Director Deferred Compensation Plan (the "Plan"), representing an exempt transaction under the Plan. The number of shares of phantom stock credited to the reporting person's phantom stock account is determined by dividing the amount of deferred eligible director fees by the closing price of a share of Issuer common stock on the award date. F3 · derivative.exercise_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F3 · derivative.expiration_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F4 · balance_after: Represents the aggregate number of shares of phantom stock allocated to the reporting person under the Plan as of the award date based on the closing price of a share of the Issuer's common stock on the award date. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 20:19 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantDeferred Compensation Plan Phantom Stock · Derivative | 423 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052202 · doc4.xml · derivative · entry 2 Margulies Anne H. · CIK 0001743156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,870 Underlying: Common Stock, par value $0.01 per share · 423 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of the Issuer's common stock. F2 · shares: Represents the number of shares of phantom stock credited to the reporting person's phantom stock account pursuant to the Issuer's Non-Employee Director Deferred Compensation Plan (the "Plan"), representing an exempt transaction under the Plan. The number of shares of phantom stock credited to the reporting person's phantom stock account is determined by dividing the amount of deferred eligible director fees by the closing price of a share of Issuer common stock on the award date. F3 · derivative.exercise_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F3 · derivative.expiration_date: The balance in the reporting person's phantom share account is distributed to the reporting person in Issuer common stock following the termination of the reporting person's directorship, the reporting person's death or disability or a change of control of the Issuer. F4 · balance_after: Represents the aggregate number of shares of phantom stock allocated to the reporting person under the Plan as of the award date based on the closing price of a share of the Issuer's common stock on the award date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.